Controls were 115 voluntary healthy bone marrow donors recruited at the blood bank of the Service of Immunology at the Hospital de Clínicas de Porto Alegre, most of them resident in the urban area of Porto Alegre/RS (83 women and 32 men; 86·1% European descendents and 13·9% African descendents). Individuals presenting chronic or acute diseases were excluded from the sample, as well as those presenting family history of genetic diseases (X-linked, autosomal or chromosomal abnormalities). 3-MA in vitro Amerindians and subjects

with Asiatic origin were not included. All patients were interviewed and examined according to an extensive questionnaire directed to the evaluation of end-organ damage [14]. Disease subtype was classified as follows: diffuse cutaneous SSc (truncal and acral skin tautness), limited cutaneous SSc (skin tautness restricted to extremities

and/or face) and limited SSc (sine scleroderma) [13,15]. Clinical characteristics of the disease were observed and recorded as described previously [14]. Blood samples were collected for serology [anti-nuclear antibodies (ANA), anti-centromere and anti-topoisomerase I antibodies] and DNA extraction. Pulmonary high-resolution computed tomography (HRCT) was performed in most patients. Doppler echocardiography was used to estimate the pulmonary systolic arterial pressure (PSAP), and patients with PSAP ≥ 40 mmHg were considered to have pulmonary arterial hypertension. This study was approved by the Research Ethics Board of Hospital de Clínicas de Porto Alegre (IRB0000921). www.selleckchem.com/products/OSI-906.html Farnesyltransferase All patients and controls signed a written informed consent before participating in this study. DNA was extracted from blood buffy coat using a modified salting-out technique, as described by Miller SA et al.[16]. Fifteen KIR genes (2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DS1, 2DL1, 2DL2,

2DL3, 2DL4, 2DL5, 3DL1, 3DL2, 3DL3 and 2DP1) were typed in patients and controls using a polymerase chain reaction with sequence specific primers (PCR–SSP) method, as described by Gomez-Lozano et al.[17]. For the PCR, 10 ng DNA, 50 mM MgCl2, 1 µl PCR buffer, 25 mM deoxyribonucleoside triphosphates (dNTPs), 500 nM primers, 100 nm internal control and 2·5 units of Taq polymerase were mixed in a total volume of 10 µl [internal control primers amplify a 796 base pairs (bp) fragment of the third intron of human leucocyte antigen (HLA) DRB1]. PCR products were amplified by the GeneAmp PCR system 9600 (Perkin-Elmer, Norwalk, CA, USA), with denaturation for 3 min at 94°C, followed by four cycles of 15 s at 94°C, 15 s at 65°C, 15 s at 72°C; 21 cycles of 15 s at 94°C, 15 s at 60°C, 30 s at 72°C; five cycles of 15 s at 94°C, 1 min at 55°C, 2 min at 72°C; and a final elongation step at 72°C for 7 min. The PCR products were analysed on 1% agarose gel after electrophoresis.